The combination treatment of AML cells for 24 h and 48 h significantly increased the percentage of annexin V+/PI− (early apoptotic) and annexin V+/PI+ (late apoptotic) cells compared with vehicle or single-agent treatments. The gene discussed is ANXA5; the disease is acute myeloid leukemia.